Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nautilus Biotechnology, Inc. (NAUT : NSDQ)
 
 • Company Description   
Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus Biotechnology Inc., formerly known as Arya Sciences Acquisition Corp III, is based in SEATTLE.

Number of Employees: 155

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.78 Daily Weekly Monthly
20 Day Moving Average: 579,207 shares
Shares Outstanding: 126.15 (millions)
Market Capitalization: $98.77 (millions)
Beta: 1.42
52 Week High: $3.09
52 Week Low: $0.66
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.05% -3.12%
12 Week -3.69% -15.61%
Year To Date -53.39% -55.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2701 EASTLAKE AVENUE EAST
-
SEATTLE,WA 98102
USA
ph: 206-333-2001
fax: -
investorrelations@nautilus.bio http://www.nautilus.bio
 
 • General Corporate Information   
Officers
Sujal Patel - Chief Executive Officer; President and Director
Anna Mowry - Chief Financial Officer
Michael Altman - Director
Melissa Epperly - Director
Parag Mallick - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 63909J108
SIC: 3826
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/29/25
Share - Related Items
Shares Outstanding: 126.15
Most Recent Split Date: (:1)
Beta: 1.42
Market Capitalization: $98.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.58 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/29/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.51
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 13.33%
vs. Previous Quarter: 7.14%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -31.87
12/31/24 - -30.88
ROA
06/30/25 - -
03/31/25 - -27.39
12/31/24 - -26.61
Current Ratio
06/30/25 - -
03/31/25 - 17.36
12/31/24 - 17.40
Quick Ratio
06/30/25 - -
03/31/25 - 17.36
12/31/24 - 17.40
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 1.54
12/31/24 - 1.66
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©